EU approves Sobi’s Tryngolza for severe hypertriglyceridemia
The European Commission has approved Sobi’s Tryngolza (olezarsen) for adults with severe hypertriglyceridemia (sHTG) and triglyceride levels of at least 880 mg/dL, making it the first RNA-targeted therapy authorized in the EU for this patient group.
Tryngolza is approved as an adjunct to diet, in combination with other lipid-lowering therapies. The decision extends the drug’s existing EU authorization in familial chylomicronemia syndrome and follows a positive CHMP opinion in October.
The approval is based on the Phase 3 CORE (617 patients) and CORE2 (446 patients) studies. In patients with baseline triglycerides of at least 880 mg/dL, Tryngolza cut triglycerides by up to 73 percent versus placebo at six months, an effect sustained through 12 months. A pooled analysis showed an 83 percent reduction in acute pancreatitis events over 12 months.
Around 700,000 people in the five largest EU markets are estimated to have triglyceride levels this high. Tryngolza is given once monthly by autoinjector. Sobi holds the commercial rights outside the US, Canada and China, while Ionis Pharmaceuticals, which discovered and developed the drug, sells it in the US.
The approval is “an important step forward for patients in Europe who remain at increased risk of acute pancreatitis,” says Lydia Abad-Franch, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi.
Updated: November 18, 2026, 08:35 am
Published: November 17, 2026
